Susan Galbraith on AstraZeneca’s Grand Presence at ASH25
Susan Galbraith, Executive Vice President Oncology Haematology R&D at AstraZeneca, shared on LinkedIn:
”It’s been a great few days at ASH25, and I am very proud that AstraZeneca had its largest presence to date, reflecting our haematology research strategy in action.
We shared scientific updates on our T‑cell engager research targeting CD19 and on cell therapy approaches, including our investigational BCMAxCD19 CAR‑T programme.
These efforts are focused on better understanding immune‑based approaches in blood cancers and coming away from ASH I’m encouraged by the science and collaboration I saw in action as we work to advance the next wave of blood cancer care.
For a closer look at some of these scientific developments, Anas Younes the latest article provides more detail.”
All from ASH25 featured in Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?